The Belgian Association of Clinical Research Professionals has presented its European outstanding leadership award
The Belgian Association of Clinical Research Professionals has presented its European outstanding leadership award to Jan Geissler and Dr. Georges Niset.
The group presented Geissler, director of the European Patients' Academy on Therapeutic Innovation, EUPATI) and patient advocate, with the ACRP.be award “in recognition of his exceptional performance and leadership within EUPATI, in particular by addressing training issues and by improving the availability of both patient-centric information for the public as well as educated patient experts that have the capacity and capability to contribute to R&D.”
The leadership award is presented annually to individuals who have demonstrated exceptional performance, achievement and sustained service toward the goals of ACRP and the contributions to the advancement of clinical research in general.
"I feel deeply honored to accept this award on behalf of my fellow patient advocates as well as the EUPATI team," Geissler said. "The fact that this award of research professionals is being provided to patient advocates, as well as to EUPATI being a partnership of patient organizations, academia and industry, is a reflection of the paradigm shift: patients are increasingly seen as true partners in medicines R&D. The ACRP and EUPATI share an important mission: building the capacity and capability of both clinical research professionals as well as expert patients."
The other recipient, Dr. Georges Niset, is Secretary of the Ethics Committee at Erasme-ULB in Belgium.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.